NCT02621086

Brief Summary

This is an initial pilot study to assess and investigate if any adverse symptoms occur (and also the severity of any symptoms) after consuming a food-grade Cellodextrin preparation. Volunteers will attend a short (around 30mins) medical screening visit, to make sure they are suitable to take part in the study. They will then attend 4 study visits (separated by at least a week) for around 9.5 hours each time. During the study visits 10, 20, 30, or 50g of Cellodextrin will be given as a single oral dose, in a milkshake drink, and any symptoms experienced will then be monitored via questionnaires during the study day and for the next 60 hrs, dietary intake will also be measured over this time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable obesity

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 1, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 3, 2015

Completed
2.4 years until next milestone

Study Start

First participant enrolled

April 20, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2019

Completed
Last Updated

June 4, 2019

Status Verified

June 1, 2019

Enrollment Period

7 months

First QC Date

December 1, 2015

Last Update Submit

June 3, 2019

Conditions

Keywords

Oligosaccharide, Tolerability,

Outcome Measures

Primary Outcomes (1)

  • Gastrointestinal discomfort

    Gastrointestinal discomfort assessed by visual analogue scale up to 60 hours post consumption of cellodextrin

    60 hours

Secondary Outcomes (7)

  • Diarrhoea

    60 Hours

  • Subjective Appetite

    60 Hours

  • Energy Intake

    60 Hours

  • Change in whole blood glucose concentration

    180 mins

  • Fecal microbiota

    prior to exposure to the cellodextrin preparation

  • +2 more secondary outcomes

Study Arms (4)

Level 1

EXPERIMENTAL

10g of Cellodextrin

Dietary Supplement: Cellodextrin

Level 2

EXPERIMENTAL

20g of Cellodextrin

Dietary Supplement: Cellodextrin

Level 3

EXPERIMENTAL

30g of Cellodextrin

Dietary Supplement: Cellodextrin

Level 4

EXPERIMENTAL

50g of Cellodextrin

Dietary Supplement: Cellodextrin

Interventions

CellodextrinDIETARY_SUPPLEMENT

Gastrointestinal tolerability of single ascending doses of Cellodextrins

Level 1Level 2Level 3Level 4

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-40
  • BMI 18-30 kg/m2
  • Healthy
  • Random Blood Glucose concentration below 7.8mmol/l
  • Ability to give written informed consent
  • English speaking

You may not qualify if:

  • Age \<18 or \>40 years
  • Any significant medical condition
  • Random Blood Glucose concentration above 7.8mmol/l
  • Use of regular medication (other than oral contraceptive pill)
  • Use of herbal supplements
  • History of Irritable Bowel Syndrome (IBS), food intolerances or any gastrointestinal disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

David Greenfield Human Physiology Unit

Nottingham, Notts, NG72UH, United Kingdom

Location

MeSH Terms

Conditions

Obesity

Interventions

cellodextrin

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ian A Macdonald, PhD

    The University of Nottingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: Ascending dose tolerability study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

December 1, 2015

First Posted

December 3, 2015

Study Start

April 20, 2018

Primary Completion

November 30, 2018

Study Completion

April 30, 2019

Last Updated

June 4, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations